Get started
PROCEPT BIOROBOTICS CORPPROCEPT BIOROBOTICS CORPPROCEPT BIOROBOTICS CORP

PROCEPT BIOROBOTICS CORP

No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Forecast Seasonals

PRCT trade ideas

PRCT (Procept BioRobotics Corporation) - Pennant FormationCompany Info: PROCEPT BioRobotics Corporation is a commercial-stage surgical robotics company. It focused on advancing patient care by developing transformative solutions in urology. The company develops, manufactures and sells the AquaBeam Robotic System, an advanced, image-guided, surgical robotic system for use in minimally-invasive urologic surgery with an initial focus on treating benign prostatic hyperplasia (BPH). Technical: Pennant formation after earnings thrust up. Earnings: Earnings came in good, not stellar. They recently released research on Aquablation therapy and it's benefits on treating BPH. Trade Info: I got into this trade today. Entry is at 63.80 and stop is sitting just below 60. I would resort to profit taking on the 5 EMA and 10 EMA.
NASDAQ:PRCTLong
by Kemsdale
Procept Bio Robotics (PRCT:NASDAQ) Demonstrates Robust GrowthPRCT's Aquablation Therapy Demonstrates Robust Growth Impressive Q2 Results: Aquablation Therapy Drives Strong Revenue: A Closer Look at Q2 FY'23 Performance PRCT's aquablation therapy has displayed a remarkable growth trajectory, reflected in the impressive Q2 FY'23 revenues of $57.5 million. This substantial figure underscores the therapy's effectiveness and market demand. Strategic Growth Factors: System Placements and Installed Base: Unveiling the Company's Economic Drivers The company's growth is driven by strategic economic levers, including the placement of new systems and expansion from its existing installed base. Notably, Q2 saw a record number of systems placed, further enhancing the company's growth potential. Reiterating the Recommendation: Positive Outlook: Eyeing a Promising Future Taking into account PRCT's solid performance, it is prudent to reiterate a "buy" recommendation. The company's aquablation therapy's robust growth, coupled with its strategic initiatives, supports a positive outlook. With a price objective of $40, PRCT holds promise for investors seeking potential returns. Conclusion: PRCT's aquablation therapy has showcased strong growth, evident in its substantial Q2 FY'23 revenues. The company's economic drivers, including new system placements and growth from its installed base, contribute to its success. Considering the positive trajectory, it is advisable to maintain a "buy" recommendation, with a projected price objective of $40. PRCT's performance underscores its potential for sustained growth and value generation. This content is provided for general information purposes only and is not to be taken as investment advice nor as a recommendation for any security, investment strategy or investment account.
NASDAQ:PRCTLong
by CapitalMarketsEliteGroup
Is $PRCT ready to move higher from here?Notes: * Steady up trend in a bear market * Nice earnings for the past to quarters * Recent IPO * Looking to break above its IPO base * Printed a pocket pivot, indicating institutional buying * Offering an early entry relative to its 50 day line * Sitting just above a pivotal level of 43.9 and holding it as support for the past several sessions * IPO base resistance comes in around 47.7 Technicals: Sector: Healthcare - Medical Devices Relative Strength vs. Sector: 15.62 Relative Strength vs. SP500: 4.68 U/D Ratio: 1.1 Base Depth: 182.59% Distance from breakout buy point: -4.82% Volume 54.55% above its 15 day avg. Trade Idea: * You can enter now as the volume and price are indicating of it moving higher from here. * If you want to be a bit more safe, you can wait till after earnings
NASDAQ:PRCTLong
by HaseebKhan_90
$PRCT is giving a GREAT IPO LONG opportunity todayIPO intraday trading strategy idea The share price is rising and gonna continue this trend today. The demand for shares of the company still looks higher than the supply. These and other conditions can cause a rise in the share price today. So I opened a long position from $38,23; stop-loss — $32,39; take-profit — $55,75,/MOC price. Do not view this idea as a recommendation for trading or investing. It is published only to introduce my own vision. Always do your own analysis before making deals. When you use any materials, do not rely on blind trust. You should remember that isolated deals do not give systematic profit, so trade/invest using a developed strategy. If you like my content, you can subscribe to the news and receive my fresh ideas.
NASDAQ:PRCTLong
by KozakHlib